A Agilent Technologies Inc.

Agilent Introduces Revolutionary Real-Time Cell Analyzer

(NYSE: A) today introduced a multimode real-time cell analyzer (RTCA)—the first of its kind—combining the best of non-invasive biosensor measurement with live cell imaging.

“The will revolutionize cell analysis in life science research,” said Todd Christian, Agilent vice president, and general manager of the company’s Cell Analysis Division. “Cells are continuously monitored through biosensors and imaging at predefined temporal resolutions for days or weeks, in a well-controlled, physiologically relevant environment. With one experiment, scientists can now get two vantage points into cell health and their responses to a variety of chemical or biological manipulations, giving them greater confidence in the data they collect.”

The new instrument builds on the success of the xCELLigence biosensor technology, which Agilent obtained through its acquisition of ACEA Biosciences late last year.

“The xCELLigence RTCA eSight represents the frontier of cell analysis technology by providing unparalleled information with deep biological insights into cellular function,” said Xiaobo Wang, Ph.D., who joined Agilent from ACEA, as general manager of the Flow Cytometry and Real-Time Cell Analysis Business. “The eSight is the latest addition to Agilent’s cell analysis portfolio, exemplifying our commitment to popularizing live cell, kinetic analysis in applications across a wide spectrum of research areas including cell biology, immunology, immuno-oncology, and immunotherapy.”

The system offers several key advantages:

  • Provides label-free, real-time biosensor measurements, and kinetic imaging of the same live cell populations, independently, or simultaneously.
  • Monitors cell health, adhesion, morphology, proliferation, and cytolysis in primary or native cells alone or in co-culture providing unprecedented insight into cellular mechanisms and functionality.
  • Supports three fluorescence channels, a plethora of well-plate formats, an array of reporter reagents, and flexible user-defined schedules.
  • Reads a 96-well plate in 15 seconds.

The addition of the xCELLigence eSight real-time cell analyzer demonstrates Agilent’s commitment to continuing to provide trusted solutions for life science laboratories around the world.

This product is for research use only. Not for use in diagnostic procedures.

About Agilent Technologies

(NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,550 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to our . Follow Agilent on , , and .

EN
15/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch